IRD Stock Overview
A clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Opus Genetics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.18 |
| 52 Week High | US$3.40 |
| 52 Week Low | US$0.81 |
| Beta | 0.29 |
| 1 Month Change | 6.31% |
| 3 Month Change | -9.92% |
| 1 Year Change | -60.80% |
| 3 Year Change | -68.36% |
| 5 Year Change | n/a |
| Change since IPO | -80.33% |
Recent News & Updates
Recent updates
Analyst Forecasts For Ocuphire Pharma, Inc. (NASDAQ:OCUP) Are Surging Higher
Aug 19
Investors Still Aren't Entirely Convinced By Ocuphire Pharma, Inc.'s (NASDAQ:OCUP) Revenues Despite 30% Price Jump
Jul 24Companies Like Ocuphire Pharma (NASDAQ:OCUP) Are In A Position To Invest In Growth
Jul 12Slammed 26% Ocuphire Pharma, Inc. (NASDAQ:OCUP) Screens Well Here But There Might Be A Catch
May 02Ocuphire Pharma, Inc. (NASDAQ:OCUP) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Mar 15Analysts Just Shaved Their Ocuphire Pharma, Inc. (NASDAQ:OCUP) Forecasts Dramatically
May 20Ocuphire Pharma, Inc. Just Beat Revenue Estimates By 42%
Apr 02We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate
Jan 27We Think Ocuphire Pharma (NASDAQ:OCUP) Needs To Drive Business Growth Carefully
Oct 08Ocuphire completes patient enrollment for phase 2 trial of diabetic retinopathy treatment
Sep 08Ocuphire Pharma GAAP EPS of -$0.25 beats by $0.08
Aug 12Ocuphire extends IP rights for lead candidate with new U.S. patent
Aug 03Ocuphire gets new U.S. patent for its oral drug candidate APX3330 for use in diabetics
Jun 29We're Keeping An Eye On Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Rate
Jun 24Is Ocuphire Pharma (NASDAQ:OCUP) In A Good Position To Invest In Growth?
Mar 22Here's Why We're Not Too Worried About Ocuphire Pharma's (NASDAQ:OCUP) Cash Burn Situation
Oct 08Ocuphire Pharma: An Undervalued Ophthalmic Play
Aug 05Ocuphire Pharma inks licensing deal for RX-3117 with Processa Pharma
Jun 17Shareholder Returns
| IRD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 20.6% | 1.3% | 0.6% |
| 1Y | -60.8% | 7.9% | 23.7% |
Return vs Industry: IRD underperformed the US Pharmaceuticals industry which returned 7.9% over the past year.
Return vs Market: IRD underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| IRD volatility | |
|---|---|
| IRD Average Weekly Movement | 12.8% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IRD's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IRD's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 14 | George Magrath | opusgtx.com |
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy.
Opus Genetics, Inc. Fundamentals Summary
| IRD fundamental statistics | |
|---|---|
| Market cap | US$37.25m |
| Earnings (TTM) | -US$27.19m |
| Revenue (TTM) | US$8.38m |
4.4x
P/S Ratio-1.4x
P/E RatioIs IRD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IRD income statement (TTM) | |
|---|---|
| Revenue | US$8.38m |
| Cost of Revenue | US$23.77m |
| Gross Profit | -US$15.39m |
| Other Expenses | US$11.80m |
| Earnings | -US$27.19m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.86 |
| Gross Margin | -183.63% |
| Net Profit Margin | -324.45% |
| Debt/Equity Ratio | 0% |
How did IRD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/29 03:36 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Opus Genetics, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| John Newman | Canaccord Genuity |
| Kristen Kluska | Cantor Fitzgerald & Co. |